CSO Selloff

On June 11, 2026, Christian Heidbreder, Chief Scientific Officer at Indivior Pharmaceuticals (NASDAQ:INDV), sold 18,586 shares of common stock in an open‑market transaction, reducing his direct holdings from 246,509 to 227,923 shares. This represents a 7.54% reduction in his direct ownership stake and a transaction value of approximately $707,000. The sale occurred at a time when the company's share price was experiencing significant appreciation, having risen by 177% over the past year. The transaction is not considered a red flag for investors, as it was part of a pre‑arranged Rule 10b5‑1 trading plan adopted in March 2026. Indivior has been performing strongly financially, with sales and net income increasing significantly in the first quarter of 2026. The company's focus on research‑driven product development and targeted market expansion in addiction treatment has contributed to its competitive edge. Despite this transaction, investors should consider that Indivior shares have made a significant recovery from their 52‑week low and may be due for a correction.